Page last updated: 2024-11-04

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5712
CHEMBL ID333985
CHEBI ID142430
CHEBI ID93060
SCHEMBL ID187837
MeSH IDM0240257

Synonyms (115)

Synonym
MLS002172480
smr000857214
BRD-K60476892-001-02-1
EU-0101230
yc-1, powder
IDI1_002079
NCGC00016103-01
lopac-y-102
BIO2_000804
BIO2_000324
BSPBIO_000987
QTL1_000091
LOPAC0_001230
MLS001333257
MLS001333258
lificiguat
NCGC00094472-03
yc-1
yc 1
c19h16n2o2
KBIO3_000654
KBIO2_000327
KBIO2_005463
KBIO2_002895
KBIO3_000653
KBIOSS_000327
KBIOGR_000327
170632-47-0
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole
2-furanmethanol, 5-[1-(phenylmethyl)-1h-indazol-3-yl]-
nsc-728165
nsc728165
NCGC00094472-02
NCGC00094472-04
NCGC00094472-01
yc 1 compound
154453-18-6
yc-1 compound
NCGC00016103-02
Y-102
3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole
HMS1990A09
NCGC00016103-07
1-(1-benzyl-3-(5''-hydroxymethyl-2''-furyl)-indazole
[5-(1-benzyl-1h-indazol-3-yl)-furan-2-yl]-methanol
bdbm50095469
(5-(1-benzyl-1h-indazol-3-yl)furan-2-yl)methanol
CHEMBL333985 ,
HMS1362A09
HMS1792A09
[5-(1-benzylindazol-3-yl)furan-2-yl]methanol
1-benzyl-3-(5-hydroxymethyl-2-furyl)indazole
CHEBI:142430
[5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol
lificiguatum
HMS3263F22
unii-515cc1wpte
nsc 728165
515cc1wpte ,
lificiguat [inn]
CCG-205304
HMS2235B17
NCGC00016103-05
NCGC00016103-03
NCGC00016103-04
NCGC00016103-06
2-furanmethanol,5-[1-(phenylmethyl)-1h-indazol-3-yl]-
LP01230
BRD-K60476892-001-11-2
HMS3373B12
3-(5'-hydroxymethyl-2'furyl)-1-benzyl-indazole
YC1 ,
[5-(1-benzyl-1h-indazol-3-yl)furan-2-yl]methanol
gtpl5291
KUC114162N
ksc-412-005-
CS-3363
HY-14927
AKOS022180370
SCHEMBL187837
lificiguat [who-dd]
NCGC00261915-01
tox21_501230
1-benzyl-3-(5-hydroxymethyl-2-furyl)-1h-indazole
MLS006012048
5-[1-(phenylmethyl)-1h-indazol-3-yl]-2-furanmethanol
HB3521
AC-29036
HMS3649M04
HMS3403A09
1-benzyl-3-(5-hydroxymethylfur-2-yl)indazole
DTXSID70165635
CHEBI:93060
J-010636
sr-01000076202
SR-01000076202-1
yc-1(lificiguat)
5-a[1-a?phenylmethyl)-a?h-aindazol-a?-ayl]-a?-afuranmethanol
lificiguat(yc-1)
FT-0757306
yc-1; lificiguat
EX-A2409
Q27089256
SR-01000076202-7
BCP09072
3-(5/'-hydroxymethyl-2/'-furyl)-1-benzylindazole
SDCCGSBI-0051197.P002
NCGC00016103-17
1-benzyl-3-(5'-hydroxymethyl-2-furyl)indazole
AS-55797
nsc-756879
nsc756879
[5-[1-(phenylmethyl)indazol-3-yl]furan-2-yl]methanol
VGA63247
A907557

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Pharmacokinetic studies in rats showed that compound 32 exhibits modest oral bioavailability (12%)."( Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase.
Brummell, DG; Budworth, J; Burtin, GE; Campbell, RO; Chana, SS; Charles, IG; Fernandez, PA; Glen, RC; Goggin, MC; Hobbs, AJ; Kling, MR; Liu, Q; Madge, DJ; Meillerais, S; Powell, KL; Reynolds, K; Selwood, DL; Spacey, GD; Stables, JN; Tatlock, MA; Wheeler, KA; Wishart, G; Woo, CK, 2001
)
0.31
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" These properties have served to suggest YC-1 as an attractive therapeutic agent by permitting the reduction of nitrovasodilator dosage and regulating endogenous cGMP metabolism."( Prolonged exposure to YC-1 induces apoptosis in adrenomedullary endothelial and chromaffin cells through a cGMP-independent mechanism.
Ferrero, R; Torres, M, 2001
)
0.31
" Addition of SNP potentiated the relaxation effect of YC-1 and A-350619, shifting the dose-response curve to the left to 3 microM and 10 microM, respectively."( A-350619: a novel activator of soluble guanylyl cyclase.
Brioni, JD; Chang, R; Hsieh, GC; Kolasa, T; Miller, LN; Moreland, RB; Nakane, M, 2003
)
0.32
" In control (missense ODN treated) rats, forskolin elicited a leftward shift in the SNAP dose-response curves (approximately 50% reduction in SNAP EC50)."( cAMP modulates cGMP-mediated cerebral arteriolar relaxation in vivo.
Baughman, VL; Gavrilyuk, V; Pelligrino, DA; Wolde, HM; Xu, HL, 2004
)
0.32
"Human keratinocyte cells (HKCs) were isolated from child or adult foreskins and irradiated with LED light with a wavelength of 640 nm and a dosage of 12 or 24 J/cm(2)."( Light-Emitting Diode Irradiation (640 nm) Regulates Keratinocyte Migration and Cytoskeletal Reorganization Via Hypoxia-Inducible Factor-1α.
Cheng, B; Huang, C; Qian, SL; Sun, LY, 2016
)
0.43
"Our findings indicate that 20%EN is the minimally effective dosage of EN which promotes the recovery of intestinal barrier function after IRI in a rat model."( Partial Enteral Nutrition Mitigated Ischemia/Reperfusion-Induced Damage of Rat Small Intestinal Barrier.
Gao, X; Jiang, T; Li, C; Li, J; Li, N; Tian, F; Wang, X; Wu, C; Zhang, L, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
soluble guanylate cyclase activatorAny compound that binds to and activates soluble guanylate cyclase (EC 4.6.1.2).
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
platelet aggregation inhibitorA drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
vasodilator agentA drug used to cause dilation of the blood vessels.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
indazoles
indazoles
furansCompounds containing at least one furan ring.
aromatic primary alcoholAny primary alcohol in which the alcoholic hydroxy group is attached to a carbon which is itself bonded to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (80)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency32.46480.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency32.46480.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency31.62280.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency39.81075.623417.292931.6228AID2323
endonuclease IVEscherichia coliPotency0.14130.707912.432431.6228AID1708
glp-1 receptor, partialHomo sapiens (human)Potency1.41250.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency27.14140.100020.879379.4328AID488772; AID488773; AID588453; AID588456
15-lipoxygenase, partialHomo sapiens (human)Potency15.84890.012610.691788.5700AID887
phosphopantetheinyl transferaseBacillus subtilisPotency9.65600.141337.9142100.0000AID1490; AID2701
ATAD5 protein, partialHomo sapiens (human)Potency13.07620.004110.890331.5287AID493106; AID504466
Fumarate hydrataseHomo sapiens (human)Potency37.22120.00308.794948.0869AID1347053
USP1 protein, partialHomo sapiens (human)Potency11.22020.031637.5844354.8130AID743255
NFKB1 protein, partialHomo sapiens (human)Potency8.91250.02827.055915.8489AID895; AID928
TDP1 proteinHomo sapiens (human)Potency14.50150.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency25.11890.180013.557439.8107AID1460
thioredoxin glutathione reductaseSchistosoma mansoniPotency50.11870.100022.9075100.0000AID485364
Smad3Homo sapiens (human)Potency10.98120.00527.809829.0929AID588855; AID720534; AID720536
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency26.65140.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency12.58930.00137.762544.6684AID914; AID915
regulator of G-protein signaling 4Homo sapiens (human)Potency23.77810.531815.435837.6858AID504845
EWS/FLI fusion proteinHomo sapiens (human)Potency8.81410.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency56.23410.28189.721235.4813AID2326
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency10.73720.001530.607315,848.9004AID1224819; AID1224820; AID1224821
polyproteinZika virusPotency37.22120.00308.794948.0869AID1347053
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency39.81070.707936.904389.1251AID504333
arylsulfatase AHomo sapiens (human)Potency10.69101.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency17.53020.035520.977089.1251AID504332; AID588346
Bloom syndrome protein isoform 1Homo sapiens (human)Potency8.91250.540617.639296.1227AID2364; AID2528
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency39.81070.00207.533739.8107AID891
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency184.12610.01262.451825.0177AID485313
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency37.933023.934123.934123.9341AID1967
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency22.53580.316212.443531.6228AID902; AID924
cytochrome P450 2C19 precursorHomo sapiens (human)Potency10.00000.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency31.62280.00636.904339.8107AID883
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency35.48130.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency56.23410.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency39.81070.006026.168889.1251AID488953
mitogen-activated protein kinase 1Homo sapiens (human)Potency0.00500.039816.784239.8107AID995
atrial natriuretic peptide receptor 2 precursorHomo sapiens (human)Potency23.28090.00669.809418.4927AID1347050
ras-related protein Rab-9AHomo sapiens (human)Potency42.32860.00022.621531.4954AID485297
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency12.58930.004611.374133.4983AID463097
survival motor neuron protein isoform dHomo sapiens (human)Potency2.69680.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency12.58930.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency31.40230.177824.735279.4328AID488949
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency28.18380.00106.000935.4813AID944
lamin isoform A-delta10Homo sapiens (human)Potency11.22020.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency25.11890.316212.765731.6228AID881
Integrin beta-3Homo sapiens (human)Potency25.11890.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency25.11890.316211.415731.6228AID924
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Alpha-synucleinHomo sapiens (human)Potency22.85180.56239.398525.1189AID652106
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency29.02120.00638.235039.8107AID881; AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Ataxin-2Homo sapiens (human)Potency0.70790.011912.222168.7989AID588378
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency11.99550.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)IC50 (µMol)31.90000.00001.18439.6140AID157310
Histone acetyltransferase p300Homo sapiens (human)IC50 (µMol)1.30000.26004.00008.5000AID1496082
Hypoxia-inducible factor 1-alphaHomo sapiens (human)IC50 (µMol)12.58270.00072.46529.2100AID1194017; AID1330282; AID1496082; AID1653664; AID280769; AID310011; AID310012; AID310013; AID331305; AID599947; AID726052
CREB-binding proteinHomo sapiens (human)IC50 (µMol)1.30001.30006.689210.0000AID1496082
Endothelial PAS domain-containing protein 1Homo sapiens (human)IC50 (µMol)19.55000.00302.60028.5100AID1194017; AID1330282; AID280769; AID331305
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
FAD-linked sulfhydryl oxidase ALRHomo sapiens (human)AC5010.01200.00503.212622.7870AID493248
Guanylate cyclase soluble subunit beta-2Homo sapiens (human)EC10 (µMol)3.36000.04401.70203.3600AID630413
Guanylate cyclase soluble subunit alpha-2Homo sapiens (human)EC10 (µMol)3.36000.04401.70203.3600AID630413
Guanylate cyclase soluble subunit alpha-1Homo sapiens (human)EC10 (µMol)3.36000.04401.70203.3600AID630413
Guanylate cyclase soluble subunit beta-1Homo sapiens (human)EC10 (µMol)3.36000.04401.70203.3600AID630413
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (344)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cGMP biosynthetic processGuanylate cyclase soluble subunit beta-2Homo sapiens (human)
response to oxygen levelsGuanylate cyclase soluble subunit beta-2Homo sapiens (human)
cGMP-mediated signalingGuanylate cyclase soluble subunit beta-2Homo sapiens (human)
positive regulation of cardiac muscle hypertrophycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of nitric oxide mediated signal transductioncGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
T cell proliferationcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of T cell proliferationcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP catabolic processcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
oocyte developmentcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of cardiac muscle contractioncGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
relaxation of cardiac musclecGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of oocyte developmentcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cAMP-mediated signalingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
cGMP biosynthetic processGuanylate cyclase soluble subunit alpha-2Homo sapiens (human)
signal transductionGuanylate cyclase soluble subunit alpha-2Homo sapiens (human)
nitric oxide mediated signal transductionGuanylate cyclase soluble subunit alpha-2Homo sapiens (human)
positive regulation of nitric oxide mediated signal transductionGuanylate cyclase soluble subunit alpha-2Homo sapiens (human)
response to oxygen levelsGuanylate cyclase soluble subunit alpha-2Homo sapiens (human)
cGMP-mediated signalingGuanylate cyclase soluble subunit alpha-2Homo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
cGMP biosynthetic processGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
nitric oxide mediated signal transductionGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
blood circulationGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
regulation of blood pressureGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
positive regulation of nitric oxide mediated signal transductionGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
nitric oxide-cGMP-mediated signalingGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
relaxation of vascular associated smooth muscleGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
retrograde trans-synaptic signaling by nitric oxide, modulating synaptic transmissionGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
response to oxygen levelsGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
cGMP-mediated signalingGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
cGMP biosynthetic processGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
nitric oxide mediated signal transductionGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
blood circulationGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
nitric oxide-cGMP-mediated signalingGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
cellular response to nitric oxideGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
trans-synaptic signaling by nitric oxide, modulating synaptic transmissionGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
cGMP-mediated signalingGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
response to oxygen levelsGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone acetyltransferase p300Homo sapiens (human)
response to hypoxiaHistone acetyltransferase p300Homo sapiens (human)
somitogenesisHistone acetyltransferase p300Homo sapiens (human)
thigmotaxisHistone acetyltransferase p300Homo sapiens (human)
behavioral defense responseHistone acetyltransferase p300Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayHistone acetyltransferase p300Homo sapiens (human)
regulation of glycolytic processHistone acetyltransferase p300Homo sapiens (human)
protein acetylationHistone acetyltransferase p300Homo sapiens (human)
internal protein amino acid acetylationHistone acetyltransferase p300Homo sapiens (human)
apoptotic processHistone acetyltransferase p300Homo sapiens (human)
canonical NF-kappaB signal transductionHistone acetyltransferase p300Homo sapiens (human)
nervous system developmentHistone acetyltransferase p300Homo sapiens (human)
heart developmentHistone acetyltransferase p300Homo sapiens (human)
skeletal muscle tissue developmentHistone acetyltransferase p300Homo sapiens (human)
learning or memoryHistone acetyltransferase p300Homo sapiens (human)
circadian rhythmHistone acetyltransferase p300Homo sapiens (human)
animal organ morphogenesisHistone acetyltransferase p300Homo sapiens (human)
regulation of autophagyHistone acetyltransferase p300Homo sapiens (human)
negative regulation of autophagyHistone acetyltransferase p300Homo sapiens (human)
macrophage derived foam cell differentiationHistone acetyltransferase p300Homo sapiens (human)
regulation of mitochondrion organizationHistone acetyltransferase p300Homo sapiens (human)
positive regulation of neuron projection developmentHistone acetyltransferase p300Homo sapiens (human)
N-terminal peptidyl-lysine acetylationHistone acetyltransferase p300Homo sapiens (human)
internal peptidyl-lysine acetylationHistone acetyltransferase p300Homo sapiens (human)
peptidyl-lysine acetylationHistone acetyltransferase p300Homo sapiens (human)
B cell differentiationHistone acetyltransferase p300Homo sapiens (human)
platelet formationHistone acetyltransferase p300Homo sapiens (human)
lung developmentHistone acetyltransferase p300Homo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathwayHistone acetyltransferase p300Homo sapiens (human)
negative regulation of protein-containing complex assemblyHistone acetyltransferase p300Homo sapiens (human)
protein destabilizationHistone acetyltransferase p300Homo sapiens (human)
cellular response to nutrient levelsHistone acetyltransferase p300Homo sapiens (human)
cellular response to UVHistone acetyltransferase p300Homo sapiens (human)
multicellular organism growthHistone acetyltransferase p300Homo sapiens (human)
megakaryocyte developmentHistone acetyltransferase p300Homo sapiens (human)
swimmingHistone acetyltransferase p300Homo sapiens (human)
positive regulation of protein import into nucleusHistone acetyltransferase p300Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorHistone acetyltransferase p300Homo sapiens (human)
response to estrogenHistone acetyltransferase p300Homo sapiens (human)
positive regulation by host of viral transcriptionHistone acetyltransferase p300Homo sapiens (human)
fat cell differentiationHistone acetyltransferase p300Homo sapiens (human)
negative regulation of gluconeogenesisHistone acetyltransferase p300Homo sapiens (human)
transcription initiation-coupled chromatin remodelingHistone acetyltransferase p300Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone acetyltransferase p300Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone acetyltransferase p300Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATHistone acetyltransferase p300Homo sapiens (human)
protein stabilizationHistone acetyltransferase p300Homo sapiens (human)
positive regulation of DNA-binding transcription factor activityHistone acetyltransferase p300Homo sapiens (human)
face morphogenesisHistone acetyltransferase p300Homo sapiens (human)
regulation of androgen receptor signaling pathwayHistone acetyltransferase p300Homo sapiens (human)
peptidyl-lysine propionylationHistone acetyltransferase p300Homo sapiens (human)
cellular response to L-leucineHistone acetyltransferase p300Homo sapiens (human)
regulation of tubulin deacetylationHistone acetyltransferase p300Homo sapiens (human)
peptidyl-lysine crotonylationHistone acetyltransferase p300Homo sapiens (human)
peptidyl-lysine butyrylationHistone acetyltransferase p300Homo sapiens (human)
regulation of cellular response to heatHistone acetyltransferase p300Homo sapiens (human)
regulation of signal transduction by p53 class mediatorHistone acetyltransferase p300Homo sapiens (human)
positive regulation of TORC1 signalingHistone acetyltransferase p300Homo sapiens (human)
positive regulation of T-helper 17 cell lineage commitmentHistone acetyltransferase p300Homo sapiens (human)
positive regulation of chemokine-mediated signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of signaling receptor activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to hypoxiaHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of DNA-templated transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to reactive oxygen speciesHypoxia-inducible factor 1-alphaHomo sapiens (human)
angiogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to hypoxiaHypoxia-inducible factor 1-alphaHomo sapiens (human)
intracellular glucose homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
neural crest cell migrationHypoxia-inducible factor 1-alphaHomo sapiens (human)
epithelial to mesenchymal transitionHypoxia-inducible factor 1-alphaHomo sapiens (human)
embryonic placenta developmentHypoxia-inducible factor 1-alphaHomo sapiens (human)
B-1 B cell homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of endothelial cell proliferationHypoxia-inducible factor 1-alphaHomo sapiens (human)
heart loopingHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of neuroblast proliferationHypoxia-inducible factor 1-alphaHomo sapiens (human)
chondrocyte differentiationHypoxia-inducible factor 1-alphaHomo sapiens (human)
glandular epithelial cell maturationHypoxia-inducible factor 1-alphaHomo sapiens (human)
connective tissue replacement involved in inflammatory response wound healingHypoxia-inducible factor 1-alphaHomo sapiens (human)
outflow tract morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
cardiac ventricle morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
lactate metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of glycolytic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of DNA-templated transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
intracellular iron ion homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
signal transductionHypoxia-inducible factor 1-alphaHomo sapiens (human)
neuroblast proliferationHypoxia-inducible factor 1-alphaHomo sapiens (human)
lactationHypoxia-inducible factor 1-alphaHomo sapiens (human)
visual learningHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to iron ionHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of gene expressionHypoxia-inducible factor 1-alphaHomo sapiens (human)
vascular endothelial growth factor productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of vascular endothelial growth factor productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of gene expressionHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of gene expressionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of epithelial cell migrationHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to muscle activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
axonal transport of mitochondrionHypoxia-inducible factor 1-alphaHomo sapiens (human)
neural fold elevation formationHypoxia-inducible factor 1-alphaHomo sapiens (human)
cerebral cortex developmentHypoxia-inducible factor 1-alphaHomo sapiens (human)
bone mineralizationHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of bone mineralizationHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
TOR signalingHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of TOR signalingHypoxia-inducible factor 1-alphaHomo sapiens (human)
intracellular oxygen homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of chemokine productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of transforming growth factor beta2 productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
collagen metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to oxidative stressHypoxia-inducible factor 1-alphaHomo sapiens (human)
embryonic hemopoiesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
insulin secretion involved in cellular response to glucose stimulusHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusHypoxia-inducible factor 1-alphaHomo sapiens (human)
hemoglobin biosynthetic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of erythrocyte differentiationHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of angiogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of growthHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIHypoxia-inducible factor 1-alphaHomo sapiens (human)
muscle cell cellular homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of hormone biosynthetic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
digestive tract morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of nitric-oxide synthase activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
neuron apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
elastin metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
intestinal epithelial cell maturationHypoxia-inducible factor 1-alphaHomo sapiens (human)
epithelial cell differentiation involved in mammary gland alveolus developmentHypoxia-inducible factor 1-alphaHomo sapiens (human)
iris morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
retina vasculature development in camera-type eyeHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of thymocyte apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to interleukin-1Hypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to hypoxiaHypoxia-inducible factor 1-alphaHomo sapiens (human)
dopaminergic neuron differentiationHypoxia-inducible factor 1-alphaHomo sapiens (human)
mesenchymal cell apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
hypoxia-inducible factor-1alpha signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to virusHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of mitophagyHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of miRNA transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of miRNA transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of aerobic respirationHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of reactive oxygen species metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of protein neddylationHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of mesenchymal cell apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of transcription by RNA polymerase IIHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IICREB-binding proteinHomo sapiens (human)
response to hypoxiaCREB-binding proteinHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayCREB-binding proteinHomo sapiens (human)
chromatin remodelingCREB-binding proteinHomo sapiens (human)
regulation of DNA-templated transcriptionCREB-binding proteinHomo sapiens (human)
protein acetylationCREB-binding proteinHomo sapiens (human)
signal transductionCREB-binding proteinHomo sapiens (human)
canonical NF-kappaB signal transductionCREB-binding proteinHomo sapiens (human)
regulation of smoothened signaling pathwayCREB-binding proteinHomo sapiens (human)
negative regulation of transcription by RNA polymerase ICREB-binding proteinHomo sapiens (human)
N-terminal peptidyl-lysine acetylationCREB-binding proteinHomo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathwayCREB-binding proteinHomo sapiens (human)
protein destabilizationCREB-binding proteinHomo sapiens (human)
cellular response to nutrient levelsCREB-binding proteinHomo sapiens (human)
cellular response to UVCREB-binding proteinHomo sapiens (human)
homeostatic processCREB-binding proteinHomo sapiens (human)
embryonic digit morphogenesisCREB-binding proteinHomo sapiens (human)
positive regulation of DNA-templated transcriptionCREB-binding proteinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IICREB-binding proteinHomo sapiens (human)
rhythmic processCREB-binding proteinHomo sapiens (human)
protein-containing complex assemblyCREB-binding proteinHomo sapiens (human)
regulation of cellular response to heatCREB-binding proteinHomo sapiens (human)
positive regulation of protein localization to nucleusCREB-binding proteinHomo sapiens (human)
positive regulation of double-strand break repair via homologous recombinationCREB-binding proteinHomo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
response to hypoxiaEndothelial PAS domain-containing protein 1Homo sapiens (human)
angiogenesisEndothelial PAS domain-containing protein 1Homo sapiens (human)
embryonic placenta developmentEndothelial PAS domain-containing protein 1Homo sapiens (human)
blood vessel remodelingEndothelial PAS domain-containing protein 1Homo sapiens (human)
regulation of heart rateEndothelial PAS domain-containing protein 1Homo sapiens (human)
epithelial cell maturationEndothelial PAS domain-containing protein 1Homo sapiens (human)
response to oxidative stressEndothelial PAS domain-containing protein 1Homo sapiens (human)
mitochondrion organizationEndothelial PAS domain-containing protein 1Homo sapiens (human)
signal transductionEndothelial PAS domain-containing protein 1Homo sapiens (human)
visual perceptionEndothelial PAS domain-containing protein 1Homo sapiens (human)
erythrocyte differentiationEndothelial PAS domain-containing protein 1Homo sapiens (human)
lung developmentEndothelial PAS domain-containing protein 1Homo sapiens (human)
norepinephrine metabolic processEndothelial PAS domain-containing protein 1Homo sapiens (human)
mRNA transcription by RNA polymerase IIEndothelial PAS domain-containing protein 1Homo sapiens (human)
surfactant homeostasisEndothelial PAS domain-containing protein 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIEndothelial PAS domain-containing protein 1Homo sapiens (human)
myoblast fate commitmentEndothelial PAS domain-containing protein 1Homo sapiens (human)
multicellular organismal-level iron ion homeostasisEndothelial PAS domain-containing protein 1Homo sapiens (human)
cellular response to hypoxiaEndothelial PAS domain-containing protein 1Homo sapiens (human)
positive regulation of cold-induced thermogenesisEndothelial PAS domain-containing protein 1Homo sapiens (human)
regulation of protein neddylationEndothelial PAS domain-containing protein 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIEndothelial PAS domain-containing protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (118)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
GTP bindingGuanylate cyclase soluble subunit beta-2Homo sapiens (human)
heme bindingGuanylate cyclase soluble subunit beta-2Homo sapiens (human)
metal ion bindingGuanylate cyclase soluble subunit beta-2Homo sapiens (human)
guanylate cyclase activityGuanylate cyclase soluble subunit beta-2Homo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
protein bindingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP bindingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
metal ion bindingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
protein bindingGuanylate cyclase soluble subunit alpha-2Homo sapiens (human)
GTP bindingGuanylate cyclase soluble subunit alpha-2Homo sapiens (human)
heme bindingGuanylate cyclase soluble subunit alpha-2Homo sapiens (human)
guanylate cyclase activityGuanylate cyclase soluble subunit alpha-2Homo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
guanylate cyclase activityGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
protein bindingGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
GTP bindingGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
heme bindingGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
signaling receptor activityGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
adenylate cyclase activityGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
guanylate cyclase activityGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
protein bindingGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
GTP bindingGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
heme bindingGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
signaling receptor activityGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
protein-containing complex bindingGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
metal ion bindingGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
cytidylate cyclase activityGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
Hsp90 protein bindingGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
transcription coregulator bindingHistone acetyltransferase p300Homo sapiens (human)
transcription coactivator bindingHistone acetyltransferase p300Homo sapiens (human)
p53 bindingHistone acetyltransferase p300Homo sapiens (human)
DNA bindingHistone acetyltransferase p300Homo sapiens (human)
chromatin bindingHistone acetyltransferase p300Homo sapiens (human)
damaged DNA bindingHistone acetyltransferase p300Homo sapiens (human)
transcription coactivator activityHistone acetyltransferase p300Homo sapiens (human)
histone acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
lysine N-acetyltransferase activity, acting on acetyl phosphate as donorHistone acetyltransferase p300Homo sapiens (human)
protein bindingHistone acetyltransferase p300Homo sapiens (human)
beta-catenin bindingHistone acetyltransferase p300Homo sapiens (human)
zinc ion bindingHistone acetyltransferase p300Homo sapiens (human)
histone H3 acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone H4 acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
acyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
nuclear receptor bindingHistone acetyltransferase p300Homo sapiens (human)
peptide N-acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone H3K18 acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone H2B acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone H3K27 acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
tau protein bindingHistone acetyltransferase p300Homo sapiens (human)
nuclear androgen receptor bindingHistone acetyltransferase p300Homo sapiens (human)
NF-kappaB bindingHistone acetyltransferase p300Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone acetyltransferase p300Homo sapiens (human)
peptide-lysine-N-acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
protein propionyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
pre-mRNA intronic bindingHistone acetyltransferase p300Homo sapiens (human)
STAT family protein bindingHistone acetyltransferase p300Homo sapiens (human)
peptide 2-hydroxyisobutyryltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone lactyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
acetylation-dependent protein bindingHistone acetyltransferase p300Homo sapiens (human)
peptide butyryltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone crotonyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone butyryltransferase activityHistone acetyltransferase p300Homo sapiens (human)
DNA-binding transcription factor bindingHistone acetyltransferase p300Homo sapiens (human)
histone H3K122 acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
chromatin DNA bindingHistone acetyltransferase p300Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificHypoxia-inducible factor 1-alphaHomo sapiens (human)
sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificHypoxia-inducible factor 1-alphaHomo sapiens (human)
cis-regulatory region sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription activator activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription repressor activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
transcription coactivator bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificHypoxia-inducible factor 1-alphaHomo sapiens (human)
p53 bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription factor activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
nuclear receptor bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
enzyme bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein kinase bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein domain specific bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
ubiquitin protein ligase bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
histone deacetylase bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein heterodimerization activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
Hsp90 protein bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
E-box bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
transcription regulator activator activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
transcription coactivator bindingCREB-binding proteinHomo sapiens (human)
p53 bindingCREB-binding proteinHomo sapiens (human)
chromatin bindingCREB-binding proteinHomo sapiens (human)
damaged DNA bindingCREB-binding proteinHomo sapiens (human)
transcription coactivator activityCREB-binding proteinHomo sapiens (human)
transcription corepressor activityCREB-binding proteinHomo sapiens (human)
histone acetyltransferase activityCREB-binding proteinHomo sapiens (human)
protein bindingCREB-binding proteinHomo sapiens (human)
zinc ion bindingCREB-binding proteinHomo sapiens (human)
acetyltransferase activityCREB-binding proteinHomo sapiens (human)
peptide N-acetyltransferase activityCREB-binding proteinHomo sapiens (human)
MRF bindingCREB-binding proteinHomo sapiens (human)
histone H3K18 acetyltransferase activityCREB-binding proteinHomo sapiens (human)
histone H3K27 acetyltransferase activityCREB-binding proteinHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCREB-binding proteinHomo sapiens (human)
peptide-lysine-N-acetyltransferase activityCREB-binding proteinHomo sapiens (human)
peptide lactyltransferase activityCREB-binding proteinHomo sapiens (human)
DNA-binding transcription factor bindingCREB-binding proteinHomo sapiens (human)
chromatin DNA bindingCREB-binding proteinHomo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
sequence-specific DNA bindingEndothelial PAS domain-containing protein 1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEndothelial PAS domain-containing protein 1Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEndothelial PAS domain-containing protein 1Homo sapiens (human)
transcription coactivator bindingEndothelial PAS domain-containing protein 1Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificEndothelial PAS domain-containing protein 1Homo sapiens (human)
protein bindingEndothelial PAS domain-containing protein 1Homo sapiens (human)
protein heterodimerization activityEndothelial PAS domain-containing protein 1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingEndothelial PAS domain-containing protein 1Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingEndothelial PAS domain-containing protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (68)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolGuanylate cyclase soluble subunit beta-2Homo sapiens (human)
guanylate cyclase complex, solubleGuanylate cyclase soluble subunit beta-2Homo sapiens (human)
cellular_componentcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytosolcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
cytosolGuanylate cyclase soluble subunit alpha-2Homo sapiens (human)
guanylate cyclase complex, solubleGuanylate cyclase soluble subunit alpha-2Homo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cytosolGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
guanylate cyclase complex, solubleGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
glutamatergic synapseGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
GABA-ergic synapseGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
cytosolGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
guanylate cyclase complex, solubleGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
presynaptic active zone cytoplasmic componentGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
glutamatergic synapseGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
cytoplasmHistone acetyltransferase p300Homo sapiens (human)
cytosolHistone acetyltransferase p300Homo sapiens (human)
nucleusHistone acetyltransferase p300Homo sapiens (human)
nucleoplasmHistone acetyltransferase p300Homo sapiens (human)
cytosolHistone acetyltransferase p300Homo sapiens (human)
chromatinHistone acetyltransferase p300Homo sapiens (human)
protein-DNA complexHistone acetyltransferase p300Homo sapiens (human)
transcription regulator complexHistone acetyltransferase p300Homo sapiens (human)
histone acetyltransferase complexHistone acetyltransferase p300Homo sapiens (human)
nucleusHypoxia-inducible factor 1-alphaHomo sapiens (human)
nucleoplasmHypoxia-inducible factor 1-alphaHomo sapiens (human)
cytoplasmHypoxia-inducible factor 1-alphaHomo sapiens (human)
cytosolHypoxia-inducible factor 1-alphaHomo sapiens (human)
nuclear bodyHypoxia-inducible factor 1-alphaHomo sapiens (human)
nuclear speckHypoxia-inducible factor 1-alphaHomo sapiens (human)
motile ciliumHypoxia-inducible factor 1-alphaHomo sapiens (human)
axon cytoplasmHypoxia-inducible factor 1-alphaHomo sapiens (human)
chromatinHypoxia-inducible factor 1-alphaHomo sapiens (human)
euchromatinHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein-containing complexHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II transcription regulator complexHypoxia-inducible factor 1-alphaHomo sapiens (human)
cytoplasmCREB-binding proteinHomo sapiens (human)
nucleusCREB-binding proteinHomo sapiens (human)
nucleoplasmCREB-binding proteinHomo sapiens (human)
cytoplasmCREB-binding proteinHomo sapiens (human)
cytosolCREB-binding proteinHomo sapiens (human)
nuclear bodyCREB-binding proteinHomo sapiens (human)
chromatinCREB-binding proteinHomo sapiens (human)
histone acetyltransferase complexCREB-binding proteinHomo sapiens (human)
transcription regulator complexCREB-binding proteinHomo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
nucleoplasmEndothelial PAS domain-containing protein 1Homo sapiens (human)
cytosolEndothelial PAS domain-containing protein 1Homo sapiens (human)
nuclear speckEndothelial PAS domain-containing protein 1Homo sapiens (human)
chromatinEndothelial PAS domain-containing protein 1Homo sapiens (human)
transcription regulator complexEndothelial PAS domain-containing protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (164)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1330310Inhibition of Orai1-mediated store operated Ca2+ entry in human MDA-MB-231 cells assessed as reduction of SERCA inhibition-induced ER release at 100 uM preincubated for 15 mins followed by CPA addition by PBX-based FLIPR assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Evaluation of known and novel inhibitors of Orai1-mediated store operated Ca
AID726046Cytotoxicity against human PC3 cells after 72 hrs by MTT assay2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Discovery of Indenopyrazoles as a New Class of Hypoxia Inducible Factor (HIF)-1 Inhibitors.
AID726047Cytotoxicity against human HeLa cells after 72 hrs by MTT assay2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Discovery of Indenopyrazoles as a New Class of Hypoxia Inducible Factor (HIF)-1 Inhibitors.
AID1551545Stimulatory activity at sGC in rabbit thoracic aorta assessed as inhibition of preconstricted aortic ring contraction2019European journal of medicinal chemistry, Jul-01, Volume: 173Synthesis and biological evaluation of pyrazolo[3,4-b]pyridine-3-yl pyrimidine derivatives as sGC stimulators for the treatment of pulmonary hypertension.
AID714188Antitumor activity against human Hep3B cells xenografted in nude mouse assessed as reduction in tumor size at 10 to 30 mg/kg/day, ip for 2 weeks (Rvb = 900 mm3)2012European journal of medicinal chemistry, Mar, Volume: 49Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.
AID1727510Inhibition of PAF-induced platelet aggregation in human platelet-rich plasma incubated for 1 min followed by PAF addition2021European journal of medicinal chemistry, Jan-01, Volume: 209Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents.
AID599946Inhibition of HIF1alpha accumulation in human HeLa cells at 30 uM incubated for 4 hrs under hypoxic conditions by Western blot2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
1-[4-(N-Benzylamino)phenyl]-3-phenylurea derivatives as a new class of hypoxia-inducible factor-1alpha inhibitors.
AID1653665Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs under normoxia condition by MTT assay2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Design, synthesis, and evaluation of indeno[2,1-c]pyrazolones for use as inhibitors against hypoxia-inducible factor (HIF)-1 transcriptional activity.
AID1776859Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs in hypoxic condition by MTT assay2021Bioorganic & medicinal chemistry, 07-01, Volume: 41A gemcitabine-based conjugate with enhanced antitumor efficacy by suppressing HIF-1α expression under hypoxia.
AID310011Inhibition of hypoxia induced HIF1-alpha transcriptional activity in human Sk-Hep1 cells by reporter gene assay2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Synthesis of (aryloxyacetylamino)-isonicotinic/nicotinic acid analogues as potent hypoxia-inducible factor (HIF)-1alpha inhibitors.
AID1776877Upregulation of p53 in human A2780 cells at 0.1 to 1 uM incubated for 24 hrs in hypoxia condition by Western blot analysis2021Bioorganic & medicinal chemistry, 07-01, Volume: 41A gemcitabine-based conjugate with enhanced antitumor efficacy by suppressing HIF-1α expression under hypoxia.
AID228808Activation of sGC Enzyme (soluble Guanylate Cyclase) in Sf21 cells infected with baculo virus in the presence of 30 nM of PAPA/NO2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase.
AID1299119Reduction of insulin-induced HIF-1 alpha expression in human HCT116 cells at 3 uM by western blot analysis2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Synthesis and biological evaluation of 1,2-dithiol-3-thiones and pyrrolo[1,2-a]pyrazines as novel hypoxia inducible factor-1 (HIF-1) inhibitor.
AID226846Inhibition of platelet aggregation induced by AA (100 uM)2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Synthesis of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole analogues as novel antiplatelet agents.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1066874Binding affinity to sGC subunit alpha-1/beta-1 catalytic domain (unknown origin) assessed as additive binding at 100 uM after 30 seconds by SPR analysis in presence of GTP2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Surface plasmon resonance using the catalytic domain of soluble guanylate cyclase allows the detection of enzyme activators.
AID308635Activation of sGC heme complex expressed in Sf9 cells at 150 uM in presence of nitric oxide relative to control2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of a phosphonate analogue of the soluble guanylate cyclase activator YC-1.
AID1066879Activation of human recombinant sGC subunit alpha-1/beta-1 using GTP as substrate assessed as cGMP production measured per ng of protein at 100 uM treated prior to DEA/NO addition measured after 2 mins by radioimmunoassay in presence of Mg2+ (Rvb = 2.21 +2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Surface plasmon resonance using the catalytic domain of soluble guanylate cyclase allows the detection of enzyme activators.
AID1776853Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 07-01, Volume: 41A gemcitabine-based conjugate with enhanced antitumor efficacy by suppressing HIF-1α expression under hypoxia.
AID293443Cytotoxicity against HL60 cells by Propidium iodide exclusion assay2007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
Synthesis of furopyrazole analogs of 1-benzyl-3-(5-hydroxymethyl-2-furyl)indazole (YC-1) as novel anti-leukemia agents.
AID1194017Inhibition of HIF1 in human HT1080 cells transfected with 5xHRE/pGL3/VEGF/E1b reporter plasmid pre-incubated for 1 hr followed by incubation under hypoxia conditions for 24 hrs by HRE-driven luciferase reporter gene assay2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
Design, synthesis, and structure-activity relationships of 1-ethylpyrazole-3-carboxamide compounds as novel hypoxia-inducible factor (HIF)-1 inhibitors.
AID1693847Antiproliferative activity against human DMS-114 cells assessed as reduction in cell proliferation measured after 2 days by MTT assay2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Design and synthesis of 14 and 15-membered macrocyclic scaffolds exhibiting inhibitory activities of hypoxia-inducible factor 1α.
AID1243200Cytotoxicity against human Hep3B cells incubated for 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Synthesis and biological evaluation of novel 3,9-substituted β-carboline derivatives as anticancer agents.
AID636731Inhibition of hypoxia-induced HIF-1 transcriptional activity by luciferase reporter assay2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Design, synthesis and insight into the structure-activity relationship of 1,3-disubstituted indazoles as novel HIF-1 inhibitors.
AID1776860Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs in hypoxic condition by MTT assay2021Bioorganic & medicinal chemistry, 07-01, Volume: 41A gemcitabine-based conjugate with enhanced antitumor efficacy by suppressing HIF-1α expression under hypoxia.
AID630416Octanol-buffer partition coefficient, log D of the compound at pH 7.42011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Acidic triazoles as soluble guanylate cyclase stimulators.
AID1243204Cytotoxicity against human 2774 cells incubated for 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Synthesis and biological evaluation of novel 3,9-substituted β-carboline derivatives as anticancer agents.
AID280770Inhibition of hypoxia induced HIF1 transcriptional activity in human AGS cells by cell-based HRE reporter assay2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
(Aryloxyacetylamino)benzoic acid analogues: A new class of hypoxia-inducible factor-1 inhibitors.
AID308633Activation of sGC heme complex expressed in Sf9 cells at 150 uM relative to control2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of a phosphonate analogue of the soluble guanylate cyclase activator YC-1.
AID1776854Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 07-01, Volume: 41A gemcitabine-based conjugate with enhanced antitumor efficacy by suppressing HIF-1α expression under hypoxia.
AID726052Inhibition of hypoxia-induced HIF1alpha transcriptional activity in human HeLa cells expressing HRE-Luc after 12 hrs by luciferase reporter gene assay2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Discovery of Indenopyrazoles as a New Class of Hypoxia Inducible Factor (HIF)-1 Inhibitors.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1330316Antagonist activity at rat TRPM8 expressed in HEK293 cells assessed as inhibition of menthol-stimulated Ca2+ flux up to 100 uM after 30 mins by calcium-4 dye based FLIPR assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Evaluation of known and novel inhibitors of Orai1-mediated store operated Ca
AID1299122Cytotoxicity against human HCT116 cells at 3 uM2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Synthesis and biological evaluation of 1,2-dithiol-3-thiones and pyrrolo[1,2-a]pyrazines as novel hypoxia inducible factor-1 (HIF-1) inhibitor.
AID1281113Cytotoxicity against human HL60 cells after 48 hrs by MTT assay2016European journal of medicinal chemistry, Mar-03, Volume: 110Synthesis and structure-activity relationship studies of novel 3,9-substituted α-carboline derivatives with high cytotoxic activity against colorectal cancer cells.
AID630413Activation of human soluble guanylate cyclase assessed as production of cGMP in presence of nitric oxide donor, SIN-1 by LC-MS enzyme assay2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Acidic triazoles as soluble guanylate cyclase stimulators.
AID1727509Inhibition of collagen-induced platelet aggregation in human platelet-rich plasma incubated for 1 min followed by collagen addition2021European journal of medicinal chemistry, Jan-01, Volume: 209Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents.
AID293466Induction of apoptosis in HT60 cells at 26 uM after 48 hrs2007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
Synthesis of furopyrazole analogs of 1-benzyl-3-(5-hydroxymethyl-2-furyl)indazole (YC-1) as novel anti-leukemia agents.
AID167641Ability to inhibit maximum constriction of phenylephrine-treated precontracted (3x10 -8 g/mL) rabbit aortic rings2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
NO-independent stimulators of soluble guanylate cyclase.
AID1243206Cytotoxicity against human Detroit 551 cells incubated for 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Synthesis and biological evaluation of novel 3,9-substituted β-carboline derivatives as anticancer agents.
AID260714Ratio of activation of sGC by compound over that of control, in absence of carbon monooxide (basal activity 33+/-3 nmol/min/mg)2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
The design and synthesis of YC-1 analogues as probes for soluble guanylate cyclase.
AID1776858Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs in hypoxic condition by MTT assay2021Bioorganic & medicinal chemistry, 07-01, Volume: 41A gemcitabine-based conjugate with enhanced antitumor efficacy by suppressing HIF-1α expression under hypoxia.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID293463Induction of HL60 cell differentiation assessed as nitroblue tetrazolium reduction activity at 26 uM after 72 hrs2007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
Synthesis of furopyrazole analogs of 1-benzyl-3-(5-hydroxymethyl-2-furyl)indazole (YC-1) as novel anti-leukemia agents.
AID1776851Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 07-01, Volume: 41A gemcitabine-based conjugate with enhanced antitumor efficacy by suppressing HIF-1α expression under hypoxia.
AID1693846Antiproliferative activity against human HCT-116 cells assessed as reduction in cell proliferation measured after 2 days by MTT assay2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Design and synthesis of 14 and 15-membered macrocyclic scaffolds exhibiting inhibitory activities of hypoxia-inducible factor 1α.
AID226849Inhibition of platelet aggregation induced by thrombin (0.1 unit/ml)2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Synthesis of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole analogues as novel antiplatelet agents.
AID310012Inhibition of hypoxia induced HIF1-alpha transcriptional activity in human Hep3B cells by reporter gene assay2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Synthesis of (aryloxyacetylamino)-isonicotinic/nicotinic acid analogues as potent hypoxia-inducible factor (HIF)-1alpha inhibitors.
AID226848Inhibition of platelet aggregation induced by PAF (2 ng/mL)2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Synthesis of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole analogues as novel antiplatelet agents.
AID280769Inhibition of hypoxia induced HIF1 transcriptional activity in human Hep3B cells by cell-based HRE reporter assay2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
(Aryloxyacetylamino)benzoic acid analogues: A new class of hypoxia-inducible factor-1 inhibitors.
AID1776852Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 07-01, Volume: 41A gemcitabine-based conjugate with enhanced antitumor efficacy by suppressing HIF-1α expression under hypoxia.
AID1776875Downregulation of HIF-1alpha in human A2780 cells at 1 uM incubated for 24 hrs in hypoxia condition by Western blot analysis relative to control2021Bioorganic & medicinal chemistry, 07-01, Volume: 41A gemcitabine-based conjugate with enhanced antitumor efficacy by suppressing HIF-1α expression under hypoxia.
AID1727511Inhibition of arachidonic acid-induced platelet aggregation in human platelet-rich plasma incubated for 1 min followed by arachidonic acid addition2021European journal of medicinal chemistry, Jan-01, Volume: 209Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents.
AID1330315Antagonist activity at rat TRPV1 expressed in HEK293 cells assessed as inhibition of capsaicin-stimulated Ca2+ flux up to 100 uM after 30 mins by calcium-4 dye based FLIPR assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Evaluation of known and novel inhibitors of Orai1-mediated store operated Ca
AID764449Cytotoxicity against human A498 cells after 48 hrs by MTT assay2013European journal of medicinal chemistry, Aug, Volume: 66Synthesis and anticancer activity of 2,4-disubstituted furo[3,2-b]indole derivatives.
AID764453Cytotoxicity against human HL60 cells after 48 hrs by MTT assay2013European journal of medicinal chemistry, Aug, Volume: 66Synthesis and anticancer activity of 2,4-disubstituted furo[3,2-b]indole derivatives.
AID477608Antitumor activity against human ACHN cells after 48 hrs by MTT assay2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Synthesis of 1-benzyl-3-(5-hydroxymethyl-2-furyl)selenolo[3,2-c]pyrazole derivatives as new anticancer agents.
AID1693844Inhibition of hypoxia-induced HIF1alpha/P300-CBP interaction mediated gene transcriptional activity in human HeLa cells co-transfected with luciferase reporter plasmid containing HRE and pRL-CMV vector incubated for 12 hrs under hypoxic condition by HRE-d2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Design and synthesis of 14 and 15-membered macrocyclic scaffolds exhibiting inhibitory activities of hypoxia-inducible factor 1α.
AID630420Inhibition of CYP1A2 at 3 uM2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Acidic triazoles as soluble guanylate cyclase stimulators.
AID1727508Inhibition of thrombin-induced platelet aggregation in human platelet-rich plasma incubated for 1 min followed by thrombin addition2021European journal of medicinal chemistry, Jan-01, Volume: 209Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents.
AID1194018Inhibition of cell proliferation of human HT1080 cells after 72 hrs by WST-8 dye based cell counting assay2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
Design, synthesis, and structure-activity relationships of 1-ethylpyrazole-3-carboxamide compounds as novel hypoxia-inducible factor (HIF)-1 inhibitors.
AID1243199Cytotoxicity against human HL60 cells incubated for 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Synthesis and biological evaluation of novel 3,9-substituted β-carboline derivatives as anticancer agents.
AID599947Inhibition of hypoxia-induced HIF1alpha transcriptional activity in HEK293 cells incubated for 16 hrs by hypoxia response element-driven luciferase reporter gene assay2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
1-[4-(N-Benzylamino)phenyl]-3-phenylurea derivatives as a new class of hypoxia-inducible factor-1alpha inhibitors.
AID1243203Cytotoxicity against human COLO205 cells incubated for 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Synthesis and biological evaluation of novel 3,9-substituted β-carboline derivatives as anticancer agents.
AID1693845Antiproliferative activity against human HeLa cells assessed as reduction in cell proliferation measured after 48 hrs by MTT assay2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Design and synthesis of 14 and 15-membered macrocyclic scaffolds exhibiting inhibitory activities of hypoxia-inducible factor 1α.
AID1330282Inhibition of hypoxia-induced HIF1 transcriptional activity in human HeLa cells measured after 12 hrs by luciferase reporter gene assay2016Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24
Development of 1-aryl-3-furanyl/thienyl-imidazopyridine templates for inhibitors against hypoxia inducible factor (HIF)-1 transcriptional activity.
AID726049Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Discovery of Indenopyrazoles as a New Class of Hypoxia Inducible Factor (HIF)-1 Inhibitors.
AID205478sGC activation was determined in the presence of [alpha-32P]GTP at a concentration of 82 uM2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Synthesis of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole analogues as novel antiplatelet agents.
AID726048Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Discovery of Indenopyrazoles as a New Class of Hypoxia Inducible Factor (HIF)-1 Inhibitors.
AID1066875Binding affinity to sGC subunit alpha-1/beta-1 catalytic domain (unknown origin) at 100 uM after 30 seconds by SPR analysis in presence of GTP2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Surface plasmon resonance using the catalytic domain of soluble guanylate cyclase allows the detection of enzyme activators.
AID1496082Inhibition of HIF-1alpha/p300/CBP (unknown origin) transcriptional activity expressed in human HeLa cells expressing HRE-Luc/CMV-Luc after 12 hrs under hypoxic condition by dual luciferase reporter gene assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Discovery of bicyclo[3,3,1]non-2-ene as a novel skeleton for HIF-1 inhibitors.
AID157310Inhibition of PDE5 from platelets2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Synthesis of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole analogues as novel antiplatelet agents.
AID1243202Cytotoxicity against human A498 cells incubated for 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Synthesis and biological evaluation of novel 3,9-substituted β-carboline derivatives as anticancer agents.
AID1496084Cytotoxicity against human HeLa cells at 0.3 to 100 uM2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Discovery of bicyclo[3,3,1]non-2-ene as a novel skeleton for HIF-1 inhibitors.
AID477576Antitumor activity against human NCI-H226 cells after 48 hrs by MTT assay2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Synthesis of 1-benzyl-3-(5-hydroxymethyl-2-furyl)selenolo[3,2-c]pyrazole derivatives as new anticancer agents.
AID1066878Binding affinity to sGC subunit alpha-1/beta-1 catalytic domain (unknown origin) assessed as occupancy relative to control2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Surface plasmon resonance using the catalytic domain of soluble guanylate cyclase allows the detection of enzyme activators.
AID1330317Antagonist activity at Cav2.2 in human SH-SY5Y cells assessed as inhibition of KCl/CaCl2-stimulated Ca2+ flux up to 100 uM after 30 mins in presence of nifedipine by Fuo-4 dye based FLIPR assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Evaluation of known and novel inhibitors of Orai1-mediated store operated Ca
AID1066877Binding affinity to full-length human recombinant sGC subunit alpha-1/beta-1 at 100 uM after 30 seconds by SPR analysis2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Surface plasmon resonance using the catalytic domain of soluble guanylate cyclase allows the detection of enzyme activators.
AID1330312Inhibition of Orai1-mediated store operated Ca2+ entry in human MDA-MB-231 cells assessed as reduction in BAPTA-induced Ca2+ depletion-stimulated SOCE activity at 100 uM preincubated for 15 mins followed by BAPTA addition in presence of extracellular Ca2+2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Evaluation of known and novel inhibitors of Orai1-mediated store operated Ca
AID1066876Binding affinity to sGC subunit alpha-1/beta-1 catalytic domain (unknown origin) at 100 uM after 30 seconds by SPR analysis2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Surface plasmon resonance using the catalytic domain of soluble guanylate cyclase allows the detection of enzyme activators.
AID1243201Cytotoxicity against human H460 cells incubated for 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Synthesis and biological evaluation of novel 3,9-substituted β-carboline derivatives as anticancer agents.
AID1243205Cytotoxicity against human SKOV3 cells incubated for 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Synthesis and biological evaluation of novel 3,9-substituted β-carboline derivatives as anticancer agents.
AID1281117Cytotoxicity against human A498 cells after 48 hrs by MTT assay2016European journal of medicinal chemistry, Mar-03, Volume: 110Synthesis and structure-activity relationship studies of novel 3,9-substituted α-carboline derivatives with high cytotoxic activity against colorectal cancer cells.
AID630419Intrinsic clearance in human liver microsomes assessed per mg of protein2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Acidic triazoles as soluble guanylate cyclase stimulators.
AID260713Ratio of activation of sGC by compound over that of control, in presence of carbon monooxide (basal activity 33+/-3 nmol/min/mg in absence of CO)2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
The design and synthesis of YC-1 analogues as probes for soluble guanylate cyclase.
AID331305Inhibition of hypoxia-induced HIF1 activation in human U251HRE cells by cell based reporter gene assay2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Design and synthesis of novel furoquinoline based inhibitors of multiple targets in the PI3K/Akt-mTOR pathway.
AID293465Induction of apoptosis in HT60 cells after 72 hrs2007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
Synthesis of furopyrazole analogs of 1-benzyl-3-(5-hydroxymethyl-2-furyl)indazole (YC-1) as novel anti-leukemia agents.
AID308637Activation of sGC heme complex expressed in Sf9 cells at 150 uM in presence of carbon monoxide relative to control2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of a phosphonate analogue of the soluble guanylate cyclase activator YC-1.
AID1653664Inhibition of HIF1alpha transcriptional activity in human HeLa cells transfected with HRE-firefly luciferase and cytomegalovirus-promoter expressing Renilla luciferase incubated for 12 hrs under 1% O2 condition by dual luciferase reporter gene assay2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Design, synthesis, and evaluation of indeno[2,1-c]pyrazolones for use as inhibitors against hypoxia-inducible factor (HIF)-1 transcriptional activity.
AID630417Apparent permeability from apical to basolateral side in dog RRCK cells2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Acidic triazoles as soluble guanylate cyclase stimulators.
AID194874Effect on the survival of rat aortic smooth muscle cells2002Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23
1-Benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole (YC-1) derivatives as novel inhibitors against sodium nitroprusside-induced apoptosis.
AID226847Inhibition of platelet aggregation induced by Collagen (10 uM)2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Synthesis of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole analogues as novel antiplatelet agents.
AID599948Inhibition of HIF1alpha accumulation in human HCT116 cells at 30 uM incubated for 4 hrs under hypoxic conditions by Western blot2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
1-[4-(N-Benzylamino)phenyl]-3-phenylurea derivatives as a new class of hypoxia-inducible factor-1alpha inhibitors.
AID310013Inhibition of hypoxia induced HIF1-alpha transcriptional activity in human AGS cells by reporter gene assay2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Synthesis of (aryloxyacetylamino)-isonicotinic/nicotinic acid analogues as potent hypoxia-inducible factor (HIF)-1alpha inhibitors.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (368)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's27 (7.34)18.2507
2000's165 (44.84)29.6817
2010's152 (41.30)24.3611
2020's24 (6.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.06 (24.57)
Research Supply Index5.94 (2.92)
Research Growth Index5.00 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.53%)5.53%
Reviews18 (4.77%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other357 (94.69%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]